Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

81.21USD
20 Oct 2017
Change (% chg)

$-0.38 (-0.47%)
Prev Close
$81.59
Open
$81.95
Day's High
$81.95
Day's Low
$80.45
Volume
9,188,325
Avg. Vol
9,520,406
52-wk High
$86.27
52-wk Low
$63.76

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $106,054.30
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.56

Financials

  Industry Sector
P/E (TTM): -- 89.38 16.52
EPS (TTM): -- -- --
ROI: -- 2.39 11.32
ROE: -- 3.35 15.18

BRIEF-Gilead announces multiple scientific presentations

* Gilead announces multiple scientific presentations demonstrating high cure rates in difficult-to-cure HCV patients and improved long-term bone and renal safety of vemlidy in HBV patients switched from viread Source text for Eikon: Further company coverage:

Oct 20 2017

FDA approves Gilead cancer gene therapy; price set at $373,000

U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.

Oct 19 2017

UPDATE 2-U.S. FDA approves Gilead cancer gene therapy; price set at $373,000

Oct 18 U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.

Oct 18 2017

BRIEF-FDA approves Gilead's CAR-T cell therapy

* FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma

Oct 18 2017

FDA approves Gilead's Yescarta cancer immunotherapy

Oct 18 A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of schedule.

Oct 18 2017

BRIEF-Gilead Sciences presents results from late-stage study ‍​

* Gilead Sciences Inc - ‍no patients in bictegravir treatment arm demonstrated treatment-emergent resistance through 48 weeks​

Oct 04 2017

BRIEF-Kevin Young to retire as Gilead Sciences COO

* Kevin Young CBE, chief operating officer, plans to retire, effective early 2018​

Sep 27 2017

BRIEF-China Food and Drug Administration approves Gilead’s Sovaldi

* China Food and drug Administration approves Gilead’s Sovaldi (sofosbuvir) for treatment of chronic Hepatitis C virus infection

Sep 25 2017

BRIEF-Gilead receives approval in Canada for expanded indication of epclusa

* Gilead receives approval in Canada for expanded indication of epclusa® (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV

Sep 21 2017

BRIEF-Gilead Sciences entered into a $6 bln term loan facility credit agreement - SEC Filing‍​

* Gilead Sciences - On September 8, 2017 co entered into a $6.0 billion term loan facility credit agreement - SEC Filing‍​

Sep 13 2017

Competitors

Earnings vs. Estimates